Regions of poliovirus protein VP1 produced in Escherichia coli induce neutralizing antibodies
- PMID: 3033273
- PMCID: PMC254121
- DOI: 10.1128/JVI.61.5.1442-1447.1987
Regions of poliovirus protein VP1 produced in Escherichia coli induce neutralizing antibodies
Abstract
Poliovirus type 1 cDNA was prepared from viral RNA encoding the VP1 capsid region of the virus by using a specific DNA primer and was cloned in Escherichia coli. DNA fragments corresponding to VP1 amino acid positions 129 to 302 (pPM5k3), 52 to 302 (pPMhae3), and 24 to 129 (pPMDxba) were incorporated into plasmid vectors designed to express Trp LE-poliovirus VP1 fusion proteins under the control of the inducible tryptophan promoter-operator system. Induction of bacterial cultures containing the plasmids resulted in the production of fusion proteins which accounted for 21% (pPMhae3), 68% (pPM5k3), and 27% (pPMDxba) of the total cell protein. The proteins were purified, and each reacted with polyclonal antibodies raised against intact virions as measured by an enzyme-linked immunosorbent assay. The sera from rabbits immunized with the bacterially produced fusion proteins pPMDxba and pPMhae3 contained poliovirus-neutralizing antibodies.
Similar articles
-
A poliovirus type 1 neutralization epitope is located within amino acid residues 93 to 104 of viral capsid polypeptide VP1.EMBO J. 1983;2(11):2019-24. doi: 10.1002/j.1460-2075.1983.tb01694.x. EMBO J. 1983. PMID: 6196195 Free PMC article.
-
Critical role of neighbouring sequences on the immunogenicity of the C3 poliovirus neutralization epitope expressed at the surface of recombinant bacteria.Vaccine. 1990 Jun;8(3):269-77. doi: 10.1016/0264-410x(90)90057-s. Vaccine. 1990. PMID: 1694613
-
The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.Dev Biol Stand. 1984;57:177-85. Dev Biol Stand. 1984. PMID: 6084609
-
Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.Res Virol. 1994 Nov-Dec;145(6):349-59. doi: 10.1016/s0923-2516(07)80040-9. Res Virol. 1994. PMID: 7535942
-
Vaccines based on recombinant antigen strategies.Dev Biol (Basel). 2001;105:189-94. Dev Biol (Basel). 2001. PMID: 11763327 Review. No abstract available.
Cited by
-
Expression and purification of polioviral proteins in E. coli, and production of antisera as reagents for immunological assays.Protein Expr Purif. 2016 Dec;128:115-22. doi: 10.1016/j.pep.2016.08.014. Epub 2016 Aug 24. Protein Expr Purif. 2016. PMID: 27565898 Free PMC article.
-
A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA.Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10320-5. doi: 10.1073/pnas.96.18.10320. Proc Natl Acad Sci U S A. 1999. PMID: 10468606 Free PMC article.
-
Mapping of viral epitopes with prokaryotic expression products.Arch Virol. 1990;110(1-2):1-24. doi: 10.1007/BF01310699. Arch Virol. 1990. PMID: 1689994 Free PMC article. Review.
-
A neutralization-resistant Theiler's virus variant produces an altered disease pattern in the mouse central nervous system.J Virol. 1989 Apr;63(4):1505-13. doi: 10.1128/JVI.63.4.1505-1513.1989. J Virol. 1989. PMID: 2538641 Free PMC article.
-
Analysis of antibody responses to predominant linear epitopes of Theiler's murine encephalomyelitis virus.J Virol. 1994 May;68(5):3324-33. doi: 10.1128/JVI.68.5.3324-3333.1994. J Virol. 1994. PMID: 7512162 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources